A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Recruiting now Phase 1/2 NCT06428409
Run by Merck Sharp & Dohme LLC · for 18 and older · All sexes
What this study is about
Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the body), or unresectable (the cancer cannot be removed with surgery). The goals of this study are to learn: * About the safety of sacituzumab tirumotecan alone or with other treatments and if people tolerate it * How many people have the cancer respond (get smaller or go away) to treatment
Who can join (things the study team will check)
✅ You may be able to join if…
- Has one of the following cancers:
- Unresectable or metastatic colorectal cancer and has received prior therapy for the cancer
- Advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) and has received prior therapy for the cancer
- Advanced and/or unresectable biliary tract cancer (BTC) and has received prior therapy for the cancer
- Advanced and/or unresectable BTC and has not received prior therapy for the cancer
- For participants who have received prior therapy for cancer: Has recovered from any side effects due to previous cancer treatment
🚫 You may not be able to join if…
- History of severe eye disease
- For participants who have received prior therapy for cancer: Received prior systemic anticancer therapy including investigational agents within 4 weeks before starting study intervention
- History of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids, has current pneumonitis/ILD, or has suspected ILD or pneumonitis that cannot be ruled out by standard diagnostic assessments at Screening
Where this trial is running
- UCLA ( Site 0317), Los Angeles, California, United States
- University of Colorado Anschutz Medical Campus ( Site 0299), Aurora, Colorado, United States
- University of Colorado Anschutz Medical Campus ( Site 0325), Aurora, Colorado, United States
- University of Colorado Anschutz Medical Campus ( Site 0326), Aurora, Colorado, United States
- Sibley Memorial Hospital ( Site 0310), Washington D.C., District of Columbia, United States
- University of Florida College of Medicine ( Site 0281), Gainesville, Florida, United States
- Mount Sinai Cancer Center ( Site 0287), Miami Beach, Florida, United States
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0303), Marietta, Georgia, United States
- Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0327), Mineola, New York, United States
- Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 0324), New York, New York, United States
- University of Texas MD Anderson Cancer Center ( Site 0316), Houston, Texas, United States
- Oncology and Hematology Associates of Southwest Virginia (BRCC) ( Site 0295), Roanoke, Virginia, United States
+ 43 more sites.
Who to contact
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06428409.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.